Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFrEF Polypill Implementation in Sri Lanka
NCT06831864Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bisoprolol, losartan, eplerenone and dapagliflozin in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Feasibility of recruitment and Adherence to study procedures. Started Feb 2025; status: completed.
02
Drugs
bisoprolollosartaneplerenonedapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06831864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831864.